BalanceD-HF
a Phase III, randomised, Double-blind study to evaluate the effect of Balcinrenone/Dapagliflozin, compared with dapagliflozin, on the risk of heart failure events and cardiovascular death in patients with heart failure and impaired kidney function
- Stadium
- inclusie
- Middel
- Balcinrenone/Dapagliflozine
- Populatie
- Hartfalen
- Fase
- III
- First Patient In
- 15 augustus 2024
- Last Patient In
- 12 oktober 2026
- Last Patient Last Visit
- 16 april 2027
Inclusieperiode
National Lead
dr. S. van Wijk
Cardioloog
Studiedirecteur
S. Assa
Cardioloog
Contact Kantoor
